Silicon Biosystems | GenomeWeb

Silicon Biosystems

Cellsearch is the only FDA-cleared circulating tumor cell test and is used to help manage patients with metastatic breast, prostate, and colorectal cancers.

They plan to combine Silicon’s DEPArray digital-sorting technology with Macrogen’s NGS systems to develop genomic tests for different cancers.

The companies will combine their technologies to create workflows for the next-generation sequencing of tumor cells obtained from FFPE samples. 

NEW YORK (GenomeWeb News) – PGXL Technologies today said that it has been awarded a $300,000 contract from the National Cancer Institute to advance research directed at circulating tumor cells for the early detection of cancer.

Silicon Biosystems believes that its recent acquisition by the Menarini Group, an Italian pharmaceutical company, will provide it with the support to move its cell array platform into the clinical market.

NEW YORK (GenomeWeb News) – Italian pharmaceutical and diagnostics firm the Menarini Group has acquired Bologna-based Silicon Biosystems for an undisclosed sum, the firms announced today.

NEW YORK (GenomeWeb News) – PGXL Technologies and Silicon Biosystems today announced a deal to make Silicon Bio's DEPArray technology available through PGXL.

The California Institute of Technology of Pasadena, Calif., and the University of California of Oakland have received US Patent No.

NEW YORK (GenomeWeb News) – Transgenomic said in a document filed with the US Securities and Exchange Commission this week that its shareholders have approved an increase in the number of authorized shares of the firm's common stock from 100 million to 150 million.

This story was originally posted on Dec. 1
Baylor College of Medicine will use Silicon Biosystems' DEPArray platform in research programs related to prenatal diagnostics and molecular oncology, the firm said last week.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.